An Indian pharmaceutical company has received the USFDA’s approval for its oral tablet containing sitagliptin and metformin hydrochloride to treat type 2 diabetes patients. The extended-release tablets are recommended as an adjunct to diet and exercise to improve glycemic control in adult type 2 diabetes patients. The Drug Combo of sitagliptin and metformin An oral combination treatment of sitagliptin and metformin is used to lower blood glucose levels in adults with type 2 diabetes, alongside diet and exercise.
Sitagliptin works by increasing insulin release and decreasing glucagon levels by inhibiting the enzyme dipeptidyl peptidase 4 (DPP-4), which inactivates incretin hormones. These hormones, released by the intestine in response to food, are crucial for regulating insulin and glucagon. Metformin enhances insulin sensitivity, increasing the ability of cells to uptake glucose, and…
